A sharp divergence defined Tuesday's trading session: the Nasdaq fell over 1% despite strong tech earnings, while precious metals staged a dramatic rebound. Investor sentiment was caught between robust corporate results, hawkish Fed signals, and the ongoing partial government shutdown.
Bitcoin's recovery falters, slipping back toward $77,000 as precious metals rally sharply. The shift highlights a broader risk-off mood, with AI-related tech stocks also under pressure.
Shares of insurance software provider Guidewire Software plunged nearly 10% in morning trading, caught in a sector-wide downturn as investors reassess traditional SaaS models against the rising tide of AI integration.
Amid growing geopolitical tensions, EU Financial Services Commissioner Maria Luís Albuquerque has called for Europe to assert control over foundational technologies, highlighting cybersecurity risks and economic vulnerabilities tied to foreign tech dependence.
Shares of Trane Technologies surged following a robust quarterly report, with CNBC's Jim Cramer highlighting the HVAC giant's performance as a sign of strength in the industrial sector amid broader market volatility.
Cimpress (CMPR) stock reached a new 52-week peak, buoyed by robust technical indicators and a perfect 'Buy' rating from Barchart. While analyst targets vary widely, the company's momentum and valuation in the printing and design sector are drawing investor attention.
Shares of Universal Technical Institute (UTI) have climbed nearly 17% in a month, reigniting the debate over its valuation. With revenue topping $835 million and a five-year return of over 350%, investors are weighing strong performance against premium multiples.
Legend Biotech shares have plummeted nearly 50% in three months, erasing billions in market value and forcing investors to question whether the selloff is an overreaction or a prudent reassessment of the CAR-T leader's long-term prospects.
Shares of Richtech Robotics (RR) edged higher while options traders displayed a mixed but leaning-bullish stance, with a notable increase in demand for downside protection as the company's crucial earnings report approaches.
Even in the high-flying technology sector, compelling bargains exist. We examine three AI leaders whose current valuations may not fully reflect their long-term growth trajectories.
New data highlights a historical 'Monday effect' for tech stocks, but seasoned analysts warn that fixating on calendar patterns is a distraction from the real drivers of volatility and long-term returns.
Major fintech firms like Stripe, PayPal, and Affirm are actively pursuing state and federal banking licenses, seeking not just cost savings but greater control, regulatory simplicity, and a direct line to core financial infrastructure.
Despite fluctuating oil revenues, Abu Dhabi's BlueFive Capital has closed a massive $3 billion fund targeting AI and biotech in Western markets, signaling the Gulf's sustained financial clout and strategic pivot towards high-growth technology sectors.
Major Wall Street firms have issued contrasting ratings adjustments for two tech giants, with Adobe facing a downgrade amid growth concerns while Palantir secures an upgrade following strong government contract performance.
RBC Capital has significantly lowered its price target for Roper Technologies, highlighting investor concerns over slowing organic growth and soft spots in its software portfolio, while the company's own 2026 forecast falls short of Wall Street expectations.
Bio-Techne's shares have rebounded to around $65, but a deep dive into valuation metrics reveals a complex picture. While a discounted cash flow model suggests the stock is near fair value, its sky-high P/E ratio tells a different story, raising questions about its long-term prospects.
Strong quarterly results and bullish guidance from data analytics firm Palantir Technologies have fueled a pre-market surge in tech stocks, setting a positive tone for Wall Street as investors digest mixed economic signals and await key earnings reports.
Recent volatility in Genscript Biotech's (SEHK:1548) share price has investors questioning its true worth. While short-term gains offer a glimmer, a deeper look reveals a stark three-year decline, setting the stage for a critical valuation debate.
Biosimilars developer Alvotech (NASDAQ: ALVO) presents a complex picture for investors, with recent short-term share price gains starkly contrasted by a punishing 57% decline over the past year. As the stock trades at a significant discount to some analyst targets, the market debates whether this signals a prime opportunity or reflects deeper, unresolved challenges.
Roche's Genentech secures exclusive global rights to a promising RNAi program from China-based SanegeneBio, which receives a $200 million upfront payment and could earn over $1.3 billion in milestones.
